New Delhi: The highly anticipated Sudeep Pharma IPO is set to open on 21st November, generating significant excitement among investors even before the subscription begins. The IPO, with a total issue size of ₹895 crore, has already created a stir in the grey market, signaling strong potential listing gains.
Grey Market Performance
As of Thursday afternoon, Sudeep Pharma shares were trading at a 19.39% premium over the issue price in the grey market. With the IPO price band set between ₹563 and ₹593 per share, the grey market premium (GMP) suggests the stock could debut at around ₹708, offering investors a potential profit of ₹115 per share at listing.
IPO Details
- Issue Size: ₹895 crore
- Price Band: ₹563 – ₹593 per share
- Subscription Period: 21st to 25th November
- Composition: ₹95 crore fresh issue and 1,34,90,726 shares offered for sale by promoters and promoter group shareholders
The funds raised through the fresh issue will primarily be used for purchasing machinery for Sudeep Pharma’s Nandesari Facility 1 in Gujarat, costing ₹75.8 crore. The remaining proceeds will support the company’s general corporate objectives.
About Sudeep Pharma
Sudeep Pharma is a technology-driven company specializing in pharmaceutical, food, and nutritional excipients, as well as specialty ingredients. The company leverages in-house technologies such as encapsulation, spray drying, granulation, trituration, liposomal preparation, and blending to enhance innovation and optimize manufacturing efficiency.
Market Sentiment
Recent IPOs in the sector have bolstered investor confidence. Companies like BillionBrain Garaj Ventures (Groww) and Physicswala saw 33% and 42% listing gains, respectively. Other names, including Pine Labs, Curis Lifesciences, and Finbud Financial Services, delivered moderate but positive gains between 10% and 16%.
With the grey market already showing robust enthusiasm, Sudeep Pharma is poised to generate significant attention on its listing day, making it one of the most-watched IPOs in the current market.
Discover more from Prime Media
Subscribe to get the latest posts sent to your email.